What difference could new Alzheimer’s disease...

We investigate how self-injecting is leading to people being hospitalised and is creating new challenges for support services.Laura Foster meets NHS endocrinologist Dr Bonnie Grant, criminologist at the University of Lincoln Dr Luke Turnock and Jon Findlay, Harm Reduction Lead at ...  Show more

We investigate the growing business of full-body MRI scans. The clinics argue they can spot diseases and problems early before people feel unwell - but critics say it’s a waste of thousands of pounds and creates unnecessary anxiety about things that may never become a problem. La ...  Show more

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ...  Show more

A new drug, Donanemab, has been hailed as a turning point in the fight against Alzheimer's after a global trial confirms it slows cognitive decline.One trial was shown to have “significantly slowed” the progression of the disease—by 35%.Earlier this year, Lecanemab, the first dru ...  Show more

A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ...  Show more